Business Context and Reporting Period
Company: Revelation Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 19, 2022
Reporting Period: Specific event date of December 19, 2022.
The Company entered into a Subscription and Investment Representation Agreement with its Chief Executive Officer, James Rolke, to issue one share of Series A Preferred Stock for $5,000.00 in cash. The transaction closed on the date of the report.
Key Financial Metrics
This filing does not contain comprehensive financial statements, revenue, profit, cash flow, or margin data. The only financial metric disclosed is the transaction value of the equity sale:
- Cash Proceeds: $5,000.00 received from the sale of one share of Series A Preferred Stock.
- Debt and Liquidity: The filing text does not provide a clear value for total debt, liquidity positions, or working capital.
Material Changes
The primary material change is the issuance of unregistered equity securities and the amendment of the Company's capital structure:
- Equity Issuance: One share of Series A Preferred Stock was issued to the CEO under Section 4(a)(2) of the Securities Act of 1933.
- Voting Rights Modification: The new Preferred Stock carries 50,000,000 votes. These votes are exercisable exclusively on proposals to amend the Restated Certificate of Incorporation to effect a reverse stock split or increase authorized common shares. The stock votes automatically in proportion to common stock votes on these specific matters.
- Dividend and Liquidation Rights: The Preferred Stock has no dividend rights and no rights to asset distributions upon liquidation or bankruptcy.
Guidance, Outlook, and Risks
Management Commentary: The filing indicates the Preferred Stock is designed to facilitate a potential reverse stock split and increase in authorized shares. The stock is redeemable at the Board's discretion or automatically upon the effectiveness of the reverse stock split amendment, with a redemption price of $5,000.00.
Risks and Contingencies:
- The Preferred Stock is not convertible into common stock or other securities.
- The voting power of the Preferred Stock is limited strictly to corporate governance actions regarding stock splits and authorized share increases.
Guidance: The filing text does not provide a clear value or statement regarding future financial guidance or operational outlook.
Investor Verification Checklist
- Verify the specific terms of the reverse stock split proposal, if any, currently under consideration by the Board.
- Confirm the total number of authorized shares of common stock and the current share count to assess the impact of the 50,000,000 votes attached to the Preferred Stock.
- Review the full text of the Certificate of Designation (Exhibit 3.1) and Subscription Agreement (Exhibit 10.1) for any additional covenants not summarized in the 8-K.
- Monitor subsequent filings for the redemption of the Preferred Stock or the implementation of the reverse stock split.